ABVX Profile
ABIVAX Société Anonyme, a clinical-stage biotechnology company headquartered in Paris, France, specializes in developing innovative therapeutics aimed at modulating the immune response in patients suffering from chronic inflammatory diseases. Founded in 2013, ABIVAX focuses on leveraging the body's natural regulatory mechanisms to create novel treatments that address significant unmet medical needs.
At the forefront of ABIVAX's pipeline is obefazimod, its lead drug candidate currently undergoing Phase 3 clinical trials. Obefazimod is being evaluated for its efficacy in treating moderately to severely active ulcerative colitis, a condition characterized by inflammation and ulcers in the colon. The drug represents a promising approach to managing this challenging disease by targeting immune system pathways.
The company's research and development efforts extend beyond obefazimod, encompassing a robust portfolio of therapeutic candidates designed to tackle various autoimmune and inflammatory disorders. ABIVAX employs a rigorous scientific approach coupled with strategic partnerships to advance its pipeline, aiming to bring new treatment options to patients worldwide.
As part of its commitment to innovation, ABIVAX continues to explore new applications for its proprietary technology platforms, which underpin the development of its therapeutic agents. With a dedicated team of researchers and clinicians, the company remains focused on translating scientific discoveries into transformative therapies that improve the lives of patients battling chronic inflammatory diseases.
|
